Breast Cancer Awareness Month 2019

Partager cette publication

This year BIG is celebrating its 20th anniversary. What better time than the month of October to spread our message of hope et progress?

Linked to thousands of hospitals and tens of thousands breast cancer experts through 57 academic research groups, BIG is the largest international network (over 50 countries across 6 continents) dedicated solely to breast cancer research. Since 1999, more than 95,000 patients have participated in BIG’s clinical trials.

Research is essential to help us better understand breast cancer.

Much of BIG’s research is considered to be landmark, introducing particularly innovative designs, contributing to significant breakthroughs, or paving the way towards more personalised treatment of the disease.

Over the course of this breast cancer awareness month, we will present these studies that have already made an impact, or that we expect to in the future:

    Les résultats de cette étude pourraient influencer la façon dont sont traitées 2 femmes sur 5 atteintes d’un cancer du sein, en identifiant celles auxquelles on pourrait éviter une radiothérapie inutile après la chirurgie.
    POSITIVE représente une opportunité unique de permettre aux jeunes femmes ayant eu un cancer du sein hormono-dépendant d’interrompre temporairement leur traitement pour essayer de concevoir un enfant.
    Le programme de recherche AURORA vise à mieux comprendre les caractéristiques moléculaires et l’évolution du cancer du sein récurrent ou métastatique, dans l’espoir de traiter plus efficacement la maladie, voire de la bloquer à l’avenir.
    Les essais cliniques internationaux randomisés SOFT & TEXT proposent une nouvelle option de traitement postopératoire pour les jeunes femmes atteintes d’un cancer du sein hormono-dépendant à un stade précoce. 
    L’essai APHINITY a révélé que, combiné au trastuzumab et à la chimiothérapie, le pertuzumab en traitement adjuvant améliorait significativement les taux de survie sans maladie invasive chez les patients atteints d’un cancer du sein opérable HER2 positif.
    The MINDACT trial found that 46% of patients identified as high-risk for cancer recurrence based on traditional factors were identified as low risk when adding the MammaPrint test.  This means that many patients who in the past would definitely have received chemotherapy, might be spared such treatment and its side effects in the future. It represents a large academic effort towards de-escalating therapies.
    The ALTTO and NeoALTTO trials represent a valuable resource for translational research as well as large scale academic collaboration. 
  • HERA
    The HERA trial indicated that one year of treatment with trastuzumab had a significant and sustained benefit in preventing cancer recurrence, contributing to a new standard treatment for HER+ breast cancer.
  • Inhibiteurs d’aromatase
    The BIG 1-97, BIG 2-97 and BIG 1-98 trials added to the body of evidence that aromatase inhibitors could be used as a safe alternative to tamoxifen.

Thanks to BIG’s 57 Member Groups and the team at BIG Headquarters, we can proudly say that we have dedicated 20 years of collective commitment to collaboration, innovation and leadership in facilitating and accelerating breast cancer research. Our aim is to deliver the best in breast cancer treatment for optimal patient outcomes.

Plus à explorer